黄斑部病变治疗市场：按类型、阶段、给药途径、销售管道和地区划分

2026年黄斑部病变治疗市场规模估计为178亿美元，预计2033年将达286亿美元。预计2026年至2033年，该市场将以5.7%的复合年增长率成长。

黄斑部病变是眼科疾病，会导致中心视力丧失。它通常是由异常血管渗漏液体或血液到黄斑引起的。老龄化黄斑部病变有两种：根治性和渗出型。目前尚无治疗方法，但治疗可以帮助延缓老龄化黄斑部病变（AMD）的进展并预防严重的视力丧失。然而，治疗方法因疾病的阶段和类型而异。萎缩型AMD的进展速度通常比渗出型AMD慢，但目前尚无核准的治疗方法或治癒手段。萎缩型AMD较为常见，但通常进展缓慢（持续数年）。然而，治疗方法因AMD的类型而异。

市场动态

视网膜疾病发病率的不断上升、老年人口的增长、对安全有效治疗方法的需求日益增长以及临床试验数量的增加，是推动全球黄斑部病变治疗市场成长的关键因素。例如，根据美国疾病管制与预防中心（CDC）的数据显示，老龄化黄斑部病变是全球主要的失明原因之一，也是65岁及以上美国人视力丧失和失明的主要原因。此外，预计到2050年，美国老年人口将从4,800万增长至8,800万，几乎翻倍。

2021 年 9 月，美国食品药物管理局(FDA) 批准了 Byooviz（ranivizumab nuna），这是Lucentis （ranivizumab 注射液）的首个生物类似药，用于治疗多种眼科疾病，核准新生血管性老龄化黄斑部病变(nAMD)，这是导緻美国人 65 岁以上的主要原因。

本次调查的主要特点。

• 本报告对全球黄斑部病变治疗市场进行了详细分析，给出了预测期（2026-2033 年）的市场规模（以十亿美元计）和复合年增长率（%），以 2025 年为基准年。
• 本报告指出了各个细分市场的潜在商机，并说明了该市场中一系列有吸引力的投资提案。
• 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的关键见解。
• 本报告根据公司概况、产品系列、主要亮点、财务表现和策略等参数，分析了全球黄斑部病变治疗市场的主要参与者。
• 透过利用本报告中提出的见解，企业行销负责人和经营团队可以就未来的产品发布、产品升级、市场扩张和行销策略做出明智的决策。
• 本报告面向该产业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
• 透过对黄斑部病变治疗市场进行各种策略性分析，相关人员将能够更轻鬆地做出决策。

目录

第一章：研究目标与前提条件

• 研究目标
• 前提
• 简称

第二章 市场范围

• 报告摘要
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

• 市场动态
  • 全球视网膜疾病负担日益加重
  • 缺乏对黄斑部病变的认识
  • 安全有效治疗方法的需求日益增长
• 影响分析
• 主要亮点
• 法规环境
• 产品上市及核准
• PEST分析
• 波特的分析
• 併购趋势

第四章：黄斑部病变治疗市场：依类型划分，2026-2033年

• 萎缩性老龄化黄斑部病变
• 渗出性老龄化黄斑部病变

第五章：黄斑部病变治疗市场：依阶段划分，2026-2033年

• 早期AMD
• AMD中期
• 后期AMD

第六章黄斑部病变治疗市场：依给药途径划分，2026-2033年

• 静脉注射
• 玻璃体内注射

第七章黄斑部病变治疗市场：依销售管道划分，2026-2033年

• 门诊手术中心
• 医院
• 其他销售管道

第八章：黄斑部病变治疗市场：依地区划分，2026-2033年

• 北美洲
• 欧洲
• 亚太地区
• 拉丁美洲
• 中东和非洲

第九章 竞争情势

• Bayer AG
• REGENXBIO Inc.
• Aerie Pharmaceutical Inc.
• Panoptica
• Pfizer Inc.
• Hoffmann-La Roche Ltd.
• Regeneron Pharmaceutical Inc.
• Novartis AG
• Bausch Health Companies Inc.

第十章

• 调查方法
• 关于本公司

Macular Degeneration Treatment Market is estimated to be valued at USD 17.8 Bn in 2026 and is expected to reach USD 28.6 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2033.

Macular Degeneration is an eye disease affecting the macula (the centre of the light-sensitive retina at the back of the eye), causing loss of central vision. It's generally caused by abnormal blood vessels that leak fluid or blood into the macula. There are 2 types of age-related macular degeneration, such as dry and wet. There is no cure, but macular degeneration (AMD) treatment help slow the disease and keep people from having a severe vision loss. However, the treatment depends on the stage and type. Dry AMD tends to progress more slowly than the wet type, and there is not, as of yet, an approved treatment or cure. The dry type is more common, but it usually progresses slowly (over years). However, treatment depends on the type of AMD.

Market Dynamics

Increasing prevalence of retinal disease, growing geriatric population, rise in demand for safe and effective treatment, and increasing number of clinical trials are major factors expected to propel growth of the global macular degeneration treatment market. For instance, according to the Centers for Disease Control and Prevention (CDC), age-related macular degeneration is a major cause of blindness worldwide and is the leading cause of vision loss and blindness for Americans aged 65 years and older, and the number of older Americans is projected to nearly double from 48 million to 88 million in 2050.

In September 2021, the United States Food and Drug Administration (FDA) approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye conditions, including neovascular age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for Americans aged 65 years and older.

Key features of the study

• This report provides in-depth analysis of the global macular degeneration treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global macular degeneration treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Bayer AG, REGENXBIO Inc., Panoptica, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, Aerie Pharmaceutical Inc., and Bausch Health Companies Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global macular degeneration treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global macular degeneration treatment market.

Market Segmentation

• By Type
  • Dry Age-related Macular Degeneration
  • Wet Age-related Macular Degeneration
• By Stage Of Disease
  • Early-stage AMD
  • Intermediate AMD
  • Late-stage AMD
• By Route Of Administration
  • Intravenous Route
  • Intravitreal Route
• By Sales Channel
  • Ambulatory Surgical Centres
  • Hospitals
  • Other Sales Channels
• By Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Bayer AG
  • REGENXBIO Inc.
  • Aerie Pharmaceutical Inc.
  • Panoptica
  • Pfizer Inc.
  • Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceutical Inc.
  • Novartis AG
  • Bausch Health Companies Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Stage of Disease
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Sales Channel
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing burden of retinal disorders worldwide
  • Lack of awareness regarding macular degeneration
  • Increasing demand for safe and effective treatment
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Macular Degeneration Treatment Market, By Type, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• Dry Age-related Macular Degeneration
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
• Wet Age-related Macular Degeneration
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)

5. Macular Degeneration Treatment Market, By Stage of Disease, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• Early-stage AMD
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
• Intermediate AMD
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
• Late-stage AMD
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)

6. Macular Degeneration Treatment Market, By Route of Administration, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• Intravenous Route
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
• Intravitreal Route
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)

7. Macular Degeneration Treatment Market, By Sales Channel, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• Ambulatory Surgical Centres
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)
• Other Sales Channels
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(USD Bn)

8. Macular Degeneration Treatment Market, By Geography, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021-2033
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Stage of Diseases, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026-2033,(USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2026-2033,(USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• REGENXBIO Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Aerie Pharmaceutical Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Panoptica
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron Pharmaceutical Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bausch Health Companies Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us